PULMOTECT, INC. is a bio-pharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.
Our technology stimulates the body’s natural defenses to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague).
Company Fact Sheet Awards
The technology has been awarded multiple grant and equity funding awards (PI of award).
Series A Round completed in 2016 Texas Emerging Technology Fund (Dr. Scott) NIH five year collaborative award with leading academic institutions (Dr. Hook) U.T.M.D. Anderson Cancer Center MRP Award (Dr. Dickey) Fannin Innovation Studio Partnership “Living Legends” fund (Dr. Dickey) Culpeper award (Dr. Evans) NCI Leukemia SPORE grant (Dr. Evans) Inaugural Texas Ignition Fund award Lehman Brothers Foundation award (Dr. Dickey) NHLBI R01 on mechanisms of inducible resistance (Dr. Evans) NHLBI/Office of the Director New Innovator Award (Dr. Evans) TJ Martell Foundation on mechanisms of inducible resistance (Dr. Evans) U.T. M. D. Anderson Cancer Center – Technology Review Committee Seven NIH SBIR awards (Dr. Scott) Cancer Prevention Research Institute of Texas (Dr. Scott) Recognition SE Bio Investor Forum winner Rice Alliance Conference, awarded a “Most Promising Company” award Top three award from SBIR National Conference World’s Best Technology Showcase presentation Top 5 company award at the national NCET2 conference in Washington DC Graduate Client Company of the Houston Technology Center American Society for Cell Biology “Press Book” selection Featured on front page of Houston Chronicle Featured in BusinessWeek, Forbes, USNews, Washington Post and multiple other media sources Selected to exhibit and showcase technology at the 2017 Biotechnology Innovation Organization conference Selected to present at the 2017 Biotech Showcase conference
Here are the